1. Auto-injector Market- Market Overview
1.1 Definitions and Scope
2. Auto-injector Market – Executive Summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by Type
2.3 Key Trends by Application
2.4 Key Trends by Geography
3. Auto-injector Market – Landscape
3.1 Comparative analysis
3.1.1 Market Share Analysis- Top Companies
3.1.2 Product Benchmarking- Top Companies
3.1.3 Top 5 Financials Analysis
3.1.4 Patent Analysis- Top Companies
3.1.5 Pricing Analysis
4. Auto-injector Market – Market Forces
4.1 Market Drivers
4.2 Market Constraints
4.3 Market Opportunities
4.4 Porters Five Force Model
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Powers of Customers
4.4.3 Threat of New Entrants
4.4.4 Rivalry Among Existing Players
4.4.5 Threat of Substitutes
5. Auto-injector Market – Strategic Analysis
5.1 Value Chain Analysis
5.2 Opportunities Analysis
5.3 Market Life Cycle
5.4 Suppliers and Distributors Analysis
6. Auto-injector Market – By Type (Market Size -$Million)
6.1 Disposable Auto-Injectors
6.2 Reusable Auto-Injectors
6.2.1 Prefilled
6.2.2 Empty
7. Auto-injector Market – By Indication (Market Size -$Million)
7.1 Rheumatoid Arthritis
7.2 Multiple Sclerosis
7.3 Diabetes
7.4 Others
8. Auto-injector Market – By End User (Market Size -$Million)
8.1 Homecare Settings
8.2 Hospitals & Clinics
8.3 Ambulatory Surgical Centers
9. Auto-injector Market – By Country (Market Size -$Million)
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 U.K
9.2.2 Germany
9.2.3 Italy
9.2.4 France
9.2.5 Russia
9.2.6 Spain
9.2.7 Denmark
9.2.8 Sweden
9.2.9 Norway
9.3 Asia Pacific
9.3.1 China
9.3.2 India
9.3.3 Japan
9.3.4 South Korea
9.3.5 Australia
9.3.6 Rest of Asia Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.5 RoW
9.5.1 Saudi Arabia
9.5.2 UAE
9.5.3 Kuwait
9.5.4 South Africa
10. Auto-injector Market – Entropy
10.1 New Product Launches
10.2 M&A’s, Collaborations, JVs and Partnerships
11. Auto-injector Market Company Analysis
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Eli Lilly
11.3 SHL Medical AG
11.4 AbbVie, Inc.
11.5 Amgen
11.6 Company 6
11.7 Company 7
11.8 Company 8
11.9 Company 9
11.10 Company 10 and more
*Financials would be provided on a best efforts basis for private companies